Drugs / R21/Matrix-MTM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06461026 | Aug 2024 → Jun 2025 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R21/Matrix-MTM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06461026 ↗ |
| Modality | Vaccine | “the R21/Matrix-MTM vaccine” NCT06461026 ↗ |
| Route | Intramuscular | “Administered intramuscularly as three total doses given four weeks apart on days 140, 168, 196.” NCT06461026 ↗ |